Skip to main content
Livermore
Livermore
ZHEN

Fairmount Funds Management LLC

SEC CIK
0001802528
Latest filing
Aug 14, 2026

Holdings in Q3 2024

Holdings as of Sep 30, 2024, filed Nov 14, 2024. Long positions only; changes compare share counts with Q2 2024.

Institution overview
Positions
15
+2 vs. Q2 2024
Portfolio value
$1.23B
+$348.2M (+39.3%) vs. Q2 2024
Filed
Nov 14, 2024
SEC
Holdings of Fairmount Funds Management LLC in Q3 2024
SecurityClassSharesValue% of portfolioShare changeActionHistory
AXSMAxsome Therapeutics, Inc.COM2,360,077$212.1M17.2%00.0%UnchangedHistory
NUVLNuvalent, Inc.COM1,687,064$172.6M14.0%−237,562−12.3%ReducedHistory
APGEApogee Therapeutics, Inc.COM2,048,647$120.3M9.8%00.0%UnchangedHistory
SYRESpyre Therapeutics, Inc.COM NEW4,018,101$118.2M9.6%00.0%UnchangedHistory
ELVNEnliven Therapeutics, Inc.COM3,202,798$81.8M6.6%00.0%UnchangedHistory
KNSAKiniksa Pharmaceuticals International, plcORD SHS CL A3,204,841$80.1M6.5%00.0%UnchangedHistory
ORKAOruka Therapeutics, Inc.COM3,211,922$78.7M6.4%+3,211,922NewHistory
VRDNViridian Therapeutics, Inc.COM3,445,813$78.4M6.4%+1,600,000+86.7%AddedHistory
DNTHDianthus Therapeutics, Inc.COM2,700,691$73.9M6.0%−62,146−2.2%ReducedHistory
COGTCogent Biosciences, Inc.COM6,225,641$67.2M5.5%00.0%UnchangedHistory
DAWNDay One Biopharmaceuticals, Inc.Stock3,103,448$43.2M3.5%+3,103,448NewHistory
ATXSAstria Therapeutics, Inc.COM3,554,129$39.1M3.2%00.0%UnchangedHistory
BCAXBicara Therapeutics Inc.COM1,284,169$32.7M2.7%+1,284,169NewHistory
ZBIOZenas BioPharma, Inc.COM1,892,806$32.0M2.6%+1,892,806NewHistory
BCYCBicycle Therapeutics PLCSPONSORED ADS123,538$2.80M0.2%−945,661−88.4%ReducedHistory

Sold out since Q2 2024 (2)

Positions held at the end of Q2 2024 that are gone from this filing.

Positions of Fairmount Funds Management LLC sold out since Q2 2024
SecurityClassShares in Q2 2024Value in Q2 2024% of portfolio in Q2 2024History
PTGXProtagonist Therapeutics, IncCOM931,890$32.3M3.6%History
TERNTerns Pharmaceuticals, Inc.COM748,996$5.10M0.6%History